Luxempart (LUX:LXMPR)

Intra-Cellular Therapies Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	30.48	183.52	46.4	498.73	156.7
Depreciation & Amortization	-0.96	0.03	0.08	0.09	0.12
Other Amortization	0.01	0.01	0.01	0.01	0.01
Loss (Gain) From Sale of Investments	0.31	-165.73	-7.91	-462.78	-120.49
Stock-Based Compensation	1.33	1.09	3.14	-	-
Other Operating Activities	0	-	-	-	-0
Change in Other Net Operating Assets	51.07	-149.26	57.32	15.02	-14.36
Operating Cash Flow	82.24	-130.34	99.03	51.06	21.97
Operating Cash Flow Growth	-	-	93.93%	132.44%	-
Capital Expenditures	-0.14	-1.12	-0.07	-0.09	-0.05
Sale of Property, Plant & Equipment	0.01	-	-	-	-
Investing Cash Flow	-0.13	-1.12	-0.07	-0.09	-0.05
Issuance of Common Stock	-	-	0.45	-	0.41
Repurchase of Common Stock	-1.04	-3.99	-	-0.19	-
Common Dividends Paid	-43.67	-39.94	-36.24	-32.17	-29.73
Other Financing Activities	25	-0	10	50	-5
Financing Cash Flow	-19.71	-43.93	-25.8	17.64	-34.31
Miscellaneous Cash Flow Adjustments	-	0	-0	-	-
Net Cash Flow	62.4	-175.39	73.16	68.62	-12.39
Free Cash Flow	82.1	-131.46	98.96	50.98	21.92
Free Cash Flow Growth	-	-	94.12%	132.54%	-
Free Cash Flow Margin	163.26%	-63.83%	146.34%	9.90%	12.87%
Free Cash Flow Per Share	3.96	-6.36	4.79	2.48	1.06
Cash Interest Paid	0.02	-	0.14	0.3	0.34
Cash Income Tax Paid	2.05	1.4	1.91	0.14	0.03
Levered Free Cash Flow	20.42	109.79	47.99	298.63	93.82
Unlevered Free Cash Flow	20.92	109.98	48.23	299.05	94.12
Change in Net Working Capital	-1.98	4.63	-16.4	14.04	3.55

Updated Sep 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.